title: 3,5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of Erigeron annuus inhibits protein glycation, aldose reductase, and cataractogenesis.
abstract: In our ongoing project directed toward the discovery of novel treatments for diabetic complications from herbal medicines, sixteen compounds including three caffeoylquinic acids and four flavonoids were isolated from an EtOAc-soluble extract of the stems and leaves of Erigeron annuus. All the isolates were evaluated in vitro for inhibitory activity on the formation of advanced glycation end products (AGEs) and rat lens aldose reductase (RLAR). Of these, 3,5-di-O-caffeoyl-epi-quinic acid (3) exhibited the most potent inhibitory activity in both the AGEs and aldose reductase (AR) assays. Compound 3 markedly reduced AGEs-bovin serum albumin (BSA) cross-linking in a dose-dependent manner. Furthermore, opacity of lenses was significantly prevented when they were treated with 3 in an ex vivo experiment.
authors.affiliation: Diabetic Complications Research Center, Division of Traditional Korean Medicine (TKM) Integrated Research, Korea Institute of Oriental Medicine, 483 Expo-ro, Yuseong-gu, Daejeon 305-811, Korea.
authors.forename: Dae Sik
authors.initials: DS
authors.lastname: Jang
authors.forename: Nam Hee
authors.initials: NH
authors.lastname: Yoo
authors.forename: Nan Hee
authors.initials: NH
authors.lastname: Kim
authors.forename: Yun Mi
authors.initials: YM
authors.lastname: Lee
authors.forename: Chan-Sik
authors.initials: CS
authors.lastname: Kim
authors.forename: Junghyun
authors.initials: J
authors.lastname: Kim
authors.forename: Joo-Hwan
authors.initials: JH
authors.lastname: Kim
authors.forename: Jin Sook
authors.initials: JS
authors.lastname: Kim
mesh_terms: D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D002386:Cataract / Q000201:enzymology / Q000378:metabolism* / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D049919:Erigeron / Q000737:chemistry; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors* / Q000378:metabolism; D007908:Lens, Crystalline / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009005:Monosaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D009924:Organ Culture Techniques; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D018515:Plant Leaves / Q000737:chemistry; D018547:Plant Stems / Q000737:chemistry; D011801:Quinic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: C500585:3,5-di-O-(E)-caffeoylquinic acid; D017127:Glycation End Products, Advanced; D009005:Monosaccharides; D010936:Plant Extracts; D011801:Quinic Acid; D000449:Aldehyde Reductase